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Purpose: Clopidogrel is metabolized by the hepatic cytochrome P450 (CYP) sys-
tem into its active thiol metabolite. CYP3A4 is involved in the metabolism of both 
clopidogrel and dihydropyridine calcium channel blockers (CCBs). A few reports 
have suggested an inhibitory interaction between CCBs and clopidogrel. Accord-
ingly, the aim of this study was to determine the effect of CCBs on the antiplatelet 
activity of clopidogrel by serial P2Y12 reaction unit (PRU) measurements. Materi-
als and Methods: We assessed changes in antiplatelet activity in patients receiving 
both clopidogrel and CCBs for at least 2 months prior to enrollment in the study. 
The antiplatelet activity of clopidogrel was measured by VerifyNow P2Y12 assay 
in the same patient while medicated with CCBs and at 8 weeks after discontinua-
tion of CCBs. After discontinuation of the CCBs, angiotensin receptor blockers 
were newly administered to the patients or dosed up for control of blood pressure. 
Results: Thirty patients finished this study. PRU significantly decreased after dis-
continuation of CCBs (238.1±74.1 vs. 215.0±69.3; p=0.001). Of the 11 patients 
with high post-treatment platelet reactivity to clopidogrel (PRU≥275), PRU de-
creased in nine patients, decreasing below the cut-off value in seven of these nine 
patients after 8 weeks. Decrease in PRU was not related to CYP2C19 genotype. 
Conclusion: CCBs inhibit the antiplatelet activity of clopidogrel.
Key Words:   Calcium channel blockers, clopidogrel, platelet reactivity unit
INTRODUCTION
Clopidogrel is one of the most widely used antiplatelet drugs in patients with acute 
coronary artery disease and cerebrovascular disease, especially those receiving cor-
onary or carotid artery stent insertion.1-4 In these patients, calcium channel blockers 
(CCBs) are commonly used to manage combined hypertension. Clopidogrel is a 
prodrug that is metabolized by the hepatic cytochrome P450 (CYP) system into its 
active thiol metabolite; this active metabolite inhibits platelet activation and recruit-
ment by blocking the adenosine diphosphate (ADP) P2Y12 receptor.5 Among the 
various CYP enzymes, CYP1A2, CYP2B6, CYP2C19, and CYP3A4/5 are in-
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Venous blood for platelet function testing was collected into 
3.2% sodium citrate tubes (Vacutainer, Becton Dickinson 
Company, Franklin Lakes, NJ, USA) using 21-G needles in a 
one-off successful attempt from a vein that had not been pre-
viously punctured. The initial 3 mL of blood was discarded 
to reduce procedure-related platelet activation.
The antiplatelet activity of clopidogrel, expressed as 
P2Y12 reaction units (PRU), was measured with the Veri-
fyNow P2Y12 assay.13 The VerifyNow P2Y12 turbidimet-
ric optical detection system measures platelet-induced ag-
gregation as an increase in light transmittance. In this assay, 
prostaglandin E1 is used in addition to ADP to increase in-
traplatelet cAMP, making the assay sensitive and specific 
for the ADP-mediated effects of the P2Y12 receptor. When 
citrate-anticoagulated whole blood is added into the assay 
device, activated platelets are exposed to fibrinogen-coated 
microparticles, and agglutination occurs in proportion to 
the number of available platelet receptors.14 Agglutination 
is recorded and reported as PRU. A higher PRU reflects 
greater ADP-mediated platelet reactivity. All measurements 
were completed within 2 hours of blood sampling. The cut-
off value of high post-treatment platelet reactivity to clopi-
dogrel (HPPR) was defined as PRU≥275.15
 
Genetic analysis
The CYP2C19 status of patients was evaluated using the See-
plex CYP2C19 ACE Genotyping system (Seegene, Seoul, 
Korea). The Seeplex CYP2C19 ACE Genotyping system is a 
simple, innovative dual priming oligonucleotide primer-based 
multiplex polymerase chain reaction system with maximal 
specificity and sensitivity for detecting two single nucleotide 
polymorphisms (CYP2C19*2, CYP2C19*3 alleles).16 Pa-
tients were classified as wild-type homozygote (*1/*1 al-
lele), heterozygote (*1/*2, *1/*3), or variant homozygote 
(*2/*2, *2/*3, *3/*3), based on the CYP2C19 genotype re-
sults, corresponding to extensive, intermediate, and poor 
metabolizers, respectively.17 We assigned extensive metab-
olizer genotypes to the good genotype group. Patients who 
were intermediate or poor metabolizers were assigned to 
the poor genotype group.
 
Statistical analysis
Statistical analyses were performed using SPSS 19.0 soft-
ware for Windows (SPSS Inc., an IBM Company, Chicago, 
volved in clopidogrel metabolism.6 CYP3A4 is also in-
volved in the metabolism of both non-dihydropyridine and 
dihydropyridine CCBs.7 A few ex vivo studies have sug-
gested an inhibitory interaction between CCBs and clopi-
dogrel.8-10 In contrast, one study showed that concomitant 
amlodipine did not impact clopidogrel-mediated platelet in-
hibition.11 However, these previous studies were retrospec-
tive studies and simply compared patients under CCB medi-
cation or not. Other confounding factors that may influence 
clopidogrel resistance, such as genetic polymorphisms and 
co-medications, were therefore not controlled. The antiplate-
let activity of clopidogrel can be inhibited by commonly 
used drugs. Atorvastatin and omeprazole have been report-
ed to have a negative impact on the antiplatelet effect of 
clopidogrel.12 To clarify the effect of CCBs on the antiplate-
let activity of clopidogrel, while controlling for other con-
founding factors, we designed a prospective study to mea-
sure antiplatelet activity twice in the same patients: during 




We enrolled patients who took clopidogrel (75 mg/day) and 
CCBs for the management of cerebrovascular disease and 
hypertension; both drugs were maintained for at least 2 
months before study enrollment. Patients who had a past 
history of adverse responses to angiotensin receptor block-
ers (ARBs) and failure to control blood pressure after dis-
continuation of CCBs were excluded. All study participants 
provided written informed consent before enrollment.
The antiplatelet activity of clopidogrel was measured two 
times by the VerifyNow P2Y12 assay (Accumetrics, San 
Diego, CA, USA): at baseline and at 8 weeks. Blood pres-
sure was measured by an oscillometric device at baseline 
and 8 weeks. After the first antiplatelet activity assay, we 
adjusted anti-hypertensive medication. We stopped CCBs 
or switched from CCBs to ARBs in patients who were tak-
ing CCBs only. Co-medication with CCBs and ARBs was 
permitted for up to 2 weeks to control blood pressure. In 
patients who had been taking both CCBs and ARBs previ-
ously, the dose of ARBs was increased and the dose of 
CCBs was decreased or stopped. After 2 weeks, CCBs were 
discontinued completely. Drug compliance during the study 
period was investigated at 8 weeks. The study protocol was 
approved by the Institutional Review Boards of the partici-
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creased in the remaining two patients. PRU was significant-
ly lower after discontinuation of CCBs in the extensive and 
intermediate genotype groups (p=0.035, p=0.043), but not 
in the poor genotype group (p=0.250). In subgroup analy-
sis, PRU was significantly lower after discontinuation of 
CCBs in both the good and poor genotype groups (p=0.035, 
p=0.021). However, there was no difference in the effect 
caused by discontinuation of CCBs according to genotype 
(p=0.669). Also, there was no difference between good and 
poor genotype when the patients were divided into two 
IL, USA). Normal distribution of interval variables was veri-
fied by the Kolmogorov-Smirnov test. Continuous variables 
were expressed as means±SD and categorical variables 
were expressed as counts (percentages). We used the paired 
t-test to determine the significance of differences in platelet 
reactivity at baseline and after discontinuation of CCBs. 
Kruskal-Wallis test was performed to determine the signifi-
cance of differences in platelet reactivity at baseline and af-
ter discontinuation of CCBs according to genotype, and 
Wilcoxon signed rank test was performed to determine the 
significance of differences between the good and poor gen-
otype groups. One way repeated measure analysis of vari-
ance (ANOVA) was performed to determine if there were 
differences in effect between the good and poor genotype 
groups and to determine if there were differences in effect 
according to the type of CCB. The χ2 test was used to as-
sess the significance of differences in demographic data ac-
cording to genotype. Kruskal-Wallis test was used to com-
pare numerical data. The level of statistical significance 




Thirty-four patients were enrolled and 30 patients finished 
this study. Four patients dropped out because of drug non-
compliance and study withdrawal. Two patients continued 
to take CCBs, while one patient did not take clopidogrel 
continuously. One patient withdrew consent for the study. 
The numbers of patients with the CYP2C19 *1/*1, *1/*2, 
*1/*3, *2/*2, *2/*3, and *3/*3 genotypes were 15 (44.1%), 
10 (29.4%), 4 (11.8%), 2 (5.9%), 2 (5.9%), and 1 (2.9%), re-
spectively. CYP2C19 genotype frequencies did not deviate 
significantly from Hardy-Weinberg equilibrium (p=0.852 
for CYP2C19*2, p=0.335 for CYP2C19*3). The character-
istics of the enrolled patients are shown in Table 1. Details 
on medication adjustment were as follows: CCBs were 
stopped in nine patients, switched to ARBs in 12 patients, 
and stopped after increasing the dose of ARBs in nine pa-
tients. PRU measured after discontinuation of CCBs was sig-
nificantly lower than that measured at baseline (215.0±69.3 
vs. 238.1±74.1, p=0.001) (Fig. 1). Based on the cut-off val-
ue for PRU of 275, 11 patients (36.7%) were categorized as 
HPPR at baseline. After 8 weeks, PRU was decreased in 9 
of the 11 HPPR patients, and in 7 of them, PRU decreased 
below 275. Therefore, only four patients remained in the 
HPPR group after discontinuation of CCBs. PRU was in-
Fig. 1. Box-and-whisker plot showing PRU as determined by the VerifyNow 
P2Y12 assay in patients at baseline and after discontinuation of CCBs. Cut-
off values of high post-treatment platelet reactivity to clopidogrel are indi-






















Baseline After discontinuation of CCBs
275





    Amlodipine 19 (63.3%)
    Benidipine   8 (26.7%)
    Others (felodipine, cilnidipine)   3 (10.0%)
ARB medication after adjustment*
    Valsartan 16 (53.3%)
    Losartan   4 (13.3%)
    Candesartan   4 (13.3%)
    Telmisartan   3 (10.0%)
    Irbesartan   2 (6.7%)
Genotype
    Extensive 14 (46.7%)
    Intermediate 12 (40.0%)
    Poor   4 (13.3%)
Duration of administered medication
    Calcium channel blocker (months) 41.6±67.9
    Clopidogrel (months) 29.0±27.4
CCB, calcium channel blockers; ARB, angiotensin receptor blockers. 
*One patient did not take ARB medication.
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cebo at 4 weeks. However, PRU increased by 21 units after 
4 weeks in the amlodipine treatment group. Although arriv-
ing at different conclusions, the present study demonstrated 
a similar trend to that in this previous study. 
Additionally, we also assessed the influence of CCBs on 
the antiplatelet activity of clopidogrel according to CY-
P2C19 genotype. A previous study reported that the anti-
platelet effect of clopidogrel in patients treated with amlo-
dipine was influenced by CYP3A5 genetic variability.18 
CYP3A5 act as a back-up enzyme for CYP3A4 when CY-
P3A4 is inhibited. One previous study reported that CY-
P2C19 polymorphism is associated with a reduced anti-
platelet effect of clopidogrel.19 However, the CYP2C19 
genotype did not influence the inhibitory effect of CCBs on 
the antiplatelet activity of clopidogrel. Discontinuation of 
CCBs decreased PRU, regardless of CYP2C19 genotype.
In the present study, we defined the cut-off PRU value of 
HPPR as 275. In a meta-analysis, PRU≥230 was associated 
with a higher rate of coronary artery disease in patients re-
ceiving percutaneous coronary intervention.20 However, the 
prevalence of reduced function variants of CYP2C19 is 
higher in Asians than Caucasians; in Koreans, it has been re-
ported to be as high as 58%.21 In a recent study, a cut-off 
PRU value of 275 best predicted thromboembolic events af-
ter percutaneous coronary intervention in Koreans. When 
we used this cut-off value, the proportion of HPPR patients 
in this study (36.7%) was similar to that reported in a previ-
ous study (36.3%).15 After discontinuation of CCBs, the pro-
portion of HPPR patients decreased from 36.7% to 13.3%. 
In seven patients (23.3%), PRU was increased after dis-
continuation of CCBs. The PRU values in these patients in-
creased by 1 to 63 and from below the cut-off level to over 
the cut-off level in one patient. We do not have an explana-
tion for the mechanism of PRU increase in these patients. 
These results might be due to allowable limits of error when 
groups (p=0.153). In the extensive genotype group, PRU 
was decreased in 10 patients and increased in four patients. 
In the intermediate genotype group, PRU was decreased in 
10 patients and increased in two patients. Also, PRU was de-
creased in three patients and increased one patient in the poor 
genotype group (Table 2). Both systolic and diastolic pres-
sures were non-significantly increased at 8 weeks compared 
to those at baseline (systolic blood pressure 124.4±14.6 vs. 
131.1±17.3, p=0.067, diastolic blood pressure 76.9±7.1 vs. 
78.5±9.9, p=0.412).
DISCUSSION
We found that concomitant use of CCBs and clopidogrel 
inhibited clopidogrel-related platelet reactivity. This is the 
first study to investigate changes in clopidogrel-related 
platelet reactivity in the same patients before and after dis-
continuation of CCBs. This study design was advantageous 
in that it allowed for the evaluation of the influences of 
CCBs while controlling for confounding factors. The con-
ditions of the patients remained the same for the duration of 
the study period except for adjustment of antihypertensive 
medication. Therefore, no other factors are likely to have 
affected the changes in clopidogrel metabolism that we ob-
served. 
The interaction between clopidogrel and CCBs has been 
inconsistently reported. The result of this study is consistent 
with previous studies.8,9 Nevertheless, one previous study 
has suggested that concomitant amlodipine use has no neg-
ative impact on clopidogrel mediated platelet inhibition.11 
The previous study was designed to compare PRU between 
amlodipine and placebo treated groups, and PRU was mea-
sured at baseline and 4 weeks. Therein, PRU was not sig-
nificantly greater in the amlodipine group compared to pla-
Table 2. Comparison of P2Y12 Reaction Units According to CYP2C19 Genotype
Characteristic Extensive Intermediate Poor p value
Number of patients 14 12 4
Age (yrs) 66.9±8.9 69.3±7.9 64.0±7.7 0.574
Male (%)   8 (57.1)   8 (66.7) 3 (75.0) 0.775
Baseline PRU 217.3±57.0 252.8±96.6 266.8±28.5 0.217
Eight wks PRU 196.8±59.6 224.0±85.0 252.0±27.7 0.215
Patients with a decreased PRU (%) 10 (71.4) 10 (83.3) 3 (75.0) 0.843
Patients with an increased PRU (%)   4 (28.6)   2 (16.7) 1 (25.0)
Duration of CCB medication   47.6±58.6   54.5±98.1   20.8±11.6 0.943
Duration of clopidogrel medication   29.0±30.7   26.1±19.7   37.5±40.1 0.900
PRU, P2Y12 reaction unit; CCB, calcium channel blocker.
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repeating the measurement, considering the small incre-
ment. As well, the CYP3A5 genotype of the patients could 
be related to these effects. 
Although mean systolic blood pressure was within the 
normal range before and after medication adjustment with 
no significant differences between baseline and 8 weeks, 
there was an increase in systolic blood pressure after chang-
ing antihypertensive drugs. It is possible that an increase in 
systolic blood pressure could increase the risk of cardiovas-
cular disease.22 A previous study showed that the extent to 
which blood pressure was lowered was associated with sec-
ondary prevention of cardiovascular disease.23 Therefore, 
we recommend that blood pressure should be cautiously 
controlled when considering whether to stop or switch from 
CCBs to other anti-hypertensive agents. 
The limitations of our study include the small numbers of 
patients examined and the lack of clinical outcome data. 
Because of our small sample size, we could not clearly de-
fine the effect of CCBs on clopidogrel resistance based on 
CYP2C19 genotype. In addition, we used several different 
ARBs to control blood pressure after discontinuing CCBs. 
Although ARBs have no known effects on clopidogrel me-
tabolism, the same ARB should be used in future studies to 
control for its possible effects. Further large prospective 
clinical studies are needed to confirm our findings and to 
determine the effect of CCBs on clinical outcomes.
In conclusion, concomitant use of CCBs can inhibit the 
antiplatelet activity of clopidogrel. It may be better to avoid 
the administration of CCBs to patients on clopidogrel med-
ication.
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